Good afternoon all, and welcome. My name is Fazi Kash, and I'll be moderating today's session. It is my pleasure to introduce Dr. Jiang, CEO and Chair; and Bill McCombe, CFO; Paul Goodson, Head of IR, ...
“Our third quarter results are encouraging and demonstrate the strength of our established brand and technology and our market leadership position,” said Wenbin Jiang, CEO of Cytek Biosciences. “As we ...
Brown Capital Management, an investment management company, released its “The Brown Capital Management Small Company Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded ...
Cytek Biosciences, Inc. (NASDAQ:CTKB) has announced the launch of its latest innovation, the Cytek Aurora Evo system, marking a significant leap forward in flow cytometry technology. Building on the ...
Cytek Biosciences (NASDAQ:CTKB – Free Report) had its price objective reduced by Morgan Stanley from $9.00 to $7.00 in a report issued on Wednesday morning,Benzinga reports. They currently have an ...
FREMONT, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Continuing its commitment to advancing cell analysis, Cytek Biosciences, Inc. (Nasdaq: CTKB) is showcasing its patented Full Spectrum Profiling™ ...
Cytek Biosciences, Inc. is highlighting its Full Spectrum Profiling™ (FSP®) technology at the upcoming CYTO 2025 and IMMUNOLOGY2025 conferences to promote advancements in cell analysis. This ...
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q4 2024 Earnings Call Transcript February 28, 2025 Operator: Thank you for standing by, and good day, everyone. My name is RG, and I will be your conference ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results